Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Payables (2016 - 2025)

Historic Payables for Trinity Biotech (TRIB) over the last 17 years, with Q2 2025 value amounting to $26.5 million.

  • Trinity Biotech's Payables rose 1478.72% to $26.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $26.5 million, marking a year-over-year increase of 1478.72%. This contributed to the annual value of $26.8 million for FY2024, which is 10920.17% up from last year.
  • As of Q2 2025, Trinity Biotech's Payables stood at $26.5 million, which was up 1478.72% from $26.8 million recorded in Q4 2024.
  • Trinity Biotech's Payables' 5-year high stood at $98.4 million during Q4 2021, with a 5-year trough of $12.2 million in Q3 2023.
  • Its 5-year average for Payables is $23.6 million, with a median of $18.3 million in 2021.
  • Per our database at Business Quant, Trinity Biotech's Payables surged by 30451.61% in 2021 and then plummeted by 8438.12% in 2022.
  • Quarter analysis of 5 years shows Trinity Biotech's Payables stood at $98.4 million in 2021, then tumbled by 84.38% to $15.4 million in 2022, then dropped by 16.73% to $12.8 million in 2023, then surged by 109.2% to $26.8 million in 2024, then fell by 1.11% to $26.5 million in 2025.
  • Its Payables was $26.5 million in Q2 2025, compared to $26.8 million in Q4 2024 and $25.3 million in Q3 2024.